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Enhanced uptake of nanoparticle drug carriers via a
thermoresponsive shell enhances cytotoxicity in a
cancer cell line†
Samer R. Abulateefeh,a,b Sebastian G. Spain,a Kristofer J. Thurecht,c
Jonathan W. Aylott,a Weng C. Chan,a Martin C. Garnetta and Cameron Alexander*a
Polymer particles consisting of a biodegradable poly[lactide-co-glycolide] (PLGA) core and a thermo-
responsive shell have been formulated to encapsulate the dye rhodamine 6G and the potent cytotoxic
drug paclitaxel. Cellular uptake of these particles is significantly enhanced above the thermal transition
temperature (TTT) of the polymer shells in the human breast carcinoma cell line MCF-7 as determined by
flow cytometry and fluorescence microscopy. Paclitaxel-loaded particles display reduced and enhanced
cytotoxicity below and above the TTT respectively compared to unencapsulated drug. The data suggests
a potential route to enhanced anti-cancer efficacy through temperature-mediated cell targeting.
Introduction
A major hurdle in the development of an efficacious drug is
delivery of an adequate dose to the target site while minimis-
ing off-target effects. This is particularly problematic for anti-
neoplastic drugs, which are typically hydrophobic compounds
with poor pharmacokinetic profiles and thus requiring repeat
administration to achieve a suitable dose. In combination with
the inherent cytotoxicity of such compounds this can lead to
significant side effects and systemic toxicity.
To overcome these limitations various methodologies have
been developed for enhanced delivery to disease sites. These
include conjugation to synthetic polymers or encapsulation
within colloidal carriers such as micelles, liposomes and nano-
particles. One area that has been recently explored is the use of
thermoresponsive colloidal systems.1–6 These aim to exploit
the slight hyperthermia (1–2 °C) displayed by certain tumour
pathologies compared to surrounding healthy tissue.7
Additionally, induced local hyperthermia is now becoming an
accepted adjunct treatment with chemo- and radiotherapy.8 By
delivering a drug in a thermoresponsive vehicle it is possible
to target the therapy to tissue at elevated temperature while
leaving other tissues unaffected.9 This is because the
hyperthermic region can be defined by the application of exter-
nal ultrasound, or by near-infra-red irradiation.10 Accordingly,
as long as a formulation can respond to the increased temp-
erature at the target site, there is the possibility to localise
therapy to this specific region through the externally directed
hyperthermia as well as through intrinsic temperature vari-
ations. An example of a thermoresponsive liposomal formu-
lation of doxorubicin is ThermoDox (Celsion Corporation),
which is currently entering Phase III trial for the treatment of
hepatocellular carcinoma. At 41–42 °C its lipid membrane
undergoes a phase transition resulting in rapid release of the
encapsulated doxorubicin. In combination with local thermal
ablation treatment the formulation response limits drug
release to the target site. Over the last few years a number of
studies have indicated possible efficacy of thermoresponsive
polymers in local drug delivery, either via controlled cell
uptake in vitro11,12 or by localisation at hyperthermic regions
in well-characterised in vivo models.13–16 We have recently
described the synthesis and characterisation of PLGA particles
with a thermoresponsive coat, via a synthesis procedure that
enables easy modification of core components as well as
response-tuning of the outer shell.17 Here we describe temp-
erature dependent cellular uptake of such particles and the
applicability to the delivery of paclitaxel in vitro (Fig. 1).
Materials and methods
Materials
Tetraethylene glycol mono bromoisobutyrate was synthesised
as previously described.17 Lactide (Aldrich, >98%), glycolide
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(Sigma, >99%), poly(ethylene glycol) methyl ether methacrylate
(PEGMEMA, Mn ca. 475, Aldrich), poly(propylene glycol)metha-
crylate (PPGMA, Mn ca. 375, Aldrich), copper(II) bromide (Alfa
Aesar, 99%), N,N,N′,N′′,N′′-pentamethyldiethylenetriamine
(PMDTA, Aldrich, 99%), tin(II) 2-ethylhexanoate (Sn(EH)2,
Aldrich, 95%), rhodamine 6G (Fluka), 2-butanone (Alfa Aesar,
99%) and paclitaxel (PTX, Sigma) were used as received. All sol-
vents were Fisher Analytical or HPLC grade and used as
received.
Instrumentation
Number average molecular weight (Mn), weight average mol-
ecular weight (Mw) and polydispersity index (Mw/Mn) of the
prepared copolymers were determined by gel permeation
chromatography (GPC) on either a Polymer Labs PL-120 or
GPC50 instrument fitted with a refractive index detector. The
columns (7.5 × 300 mm Resipore Mixed-D, 2 in series) were
eluted by chloroform and calibrated with polystyrene stan-
dards. All calibration and analysis were performed at 40 °C
and a flow rate of 1 mL min−1. Molecular weight averages and
polydispersity indices were calculated with Polymer Labs
Cirrus 3.0 software. Samples were prepared by dissolution in
chloroform and filtered (0.2 μm) prior to injection.
1H NMR spectra were recorded at 20 °C on a Bruker-DRX
instrument operating at 400 MHz. Chemical shifts (δ) are
reported in parts per million (ppm), referenced to CDCl3 (δ
7.26). The data was processed using the TOPSPIN 2 software.
Fig. 1 Schematic of the formulation of thermoresponsive nanoparticles and the proposed enhancement in cellular uptake due to change in surface corona with
thermal response. Particles at temperatures below the thermal transition temperature of their outer shell; display hydrophilic chain-extended polymers (left-hand
side) and enter cells less readily than the same particles above their polymer thermal transition temperature (TTT) (right-hand side). An increased signal from nano-
particle-encapsulated fluorescent dye is indicative of the increased uptake of particles above their TTT in cells at 40 °C (bottom right) compared to 37 °C (bottom
left).
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Synthesis of thermoresponsive polymers
Synthesis of PLGA macroinitiator (PLGA-Br). To a dry
100 mL round-bottom flask equipped with a magnetic stir bar
(0.18 g, 0.52 mmol), lactide (3.0 g, 21.0 mmol) and glycolide
(2.42 g, 21.0 mmol) were added and purged with argon for
20 min. The mixture was melted by heating up to 140 °C. The
melt was degassed and purged with Ar for a further 20 min.
This was followed by the addition of tin(II) 2-ethyl hexanoate
(42 mg, 0.1 mmol). The reaction was left stirring overnight at
140 °C. The resulting polymer was purified by dialysing
against acetone (3 × 500 mL) to afford PLGA-Br copolymer.
Mn = 12 kDa, Mw/Mn = 1.28 as determined by GPC against poly-
styrene standards. Molar composition was calculated by
1H NMR, which indicated a lactic acid : glycolic acid ratio of
1 : 1. Analytical data were in accord with previous studies.17
Synthesis of PLGA-block-(PEGMEMA-co-PPGMA). A round-
bottom flask fitted with a three-way stopcock was charged with
PLGA-Br (1.2 g, 0.1 mmol), PMDTA (17.3 mg, 0.1 mmol) and
CuBr2 (22.3 mg, 0.1 mmol). To the mixture, varying amounts
of the two co-monomers, PPGMA and PEGMEMA were used as
described previously17 to give polymers with different proper-
ties (Table S1, ESI†). All the materials were dissolved in 15 mL
of 2-butanone. The mixture was degassed by flushing with Ar
and stirred for 1 h. Tin(II) 2-ethyl hexanoate (40.5 mg,
0.1 mmol) was added under Ar. The flask was transferred to an
oil bath at 60 °C. The polymerization was terminated by
opening the flask and exposing the catalyst to air. The reaction
mixture was triturated three times using an excess of hexane :
diethyl ether (1 : 1) mixture. The precipitate was then dissolved
with chloroform and passed through an aluminum oxide
column. The resulting co-polymer was obtained by evaporating
to dryness in vacuo. The resulting copolymers were all found to
have similar overall molar masses as determined by GPC. Poly-
merisations were terminated at 60% conversion to reduce poly-
dispersity as commercially supplied PPGMA monomer can
contain small amounts of dimethacrylate impurity that leads
to markedly increased polydispersity and cross-linking at
higher conversion. Spectroscopic and other analytical data
were consistent with samples of these polymers reported in
our previous study.17
Formulation of R6G-loaded NPs
R6G-labelled NPs were prepared using an interfacial polymer
deposition (IPD) or nanoprecipitation, method based on that
of Fessi et al.18 Briefly, PLGA-b-(PEGMEMA-co-PPGMA) copoly-
mer (100 mg) was dissolved in acetone (5 mL) containing rho-
damine 6G (0.1, 0.25 or 0.4 mg). The resulting solution was
added dropwise into phosphate-buffered saline (10 mM, pH
7.4, 10 mL) with vigorous magnetic stirring. The solution was
covered with aluminium foil and left stirring in a hood over-
night at room temperature to evaporate acetone. The NP sus-
pension was purified by filtration (1.2 μm filters) followed by
size exclusion chromatography using a PD-10 desalting
column (GE Healthcare) to remove unencapsulated dye. Blank
NPs were prepared similarly for comparison purposes.
Formulation of paclitaxel (PTX)-loaded NPs
Conventional IPD method. Paclitaxel-loaded nanoparticles
were prepared using the IPD method.18 Briefly, a specific
amount of PLGA-b-(PEGMEMA-co-PPGMA) copolymer (P2) (50
or 100 mg) was dissolved in acetone (5 mL) containing a
specific amount of PTX (0.5, 1 or 2 mg). The organic solution
was added dropwise into deionised water under magnetic stir-
ring. The solution was left in an Isomat® negative pressure iso-
lator at room temperature to evaporate acetone. The particle
suspension was purified as described above.
Modified IPD method. PLGA-b-(PEGMEMA-co-PPGMA)
copolymer (P2) (100 mg) was dissolved in PTX solution
(1 mg mL−1) in acetone (1 mL). The organic solvent was allowed
to evaporate and the dried mixture was reconstituted in 5 mL
of acetone, which was then added dropwise to 10 mL water fol-
lowed by gentle magnetic stirring overnight. The solution was
left in the Isomat® negative pressure isolator at room tempera-
ture to evaporate acetone. The particle suspension was purified
as described above.
Physicochemical characterisation of
nanoparticles
Dynamic light-scattering. The hydrodynamic radii of the
nanoparticles were determined via scattered light recorded at
90° angle to incident radiation using a Viscotek Model 802
instrument equipped with an internal laser (825–832 nm) with
a maximum radiation power of 60 mW. The samples were
diluted with filtered, deionised water and at least five measure-
ments of each sample were taken. The mean and standard
deviation were calculated. Data processing was performed with
the software program OmniSize2.
Laser Doppler anemometry. Zeta potential (ζ) measure-
ments of the nanoparticles were performed by laser Doppler
anemometry using a Malvern Zetasizer 2000 equipped with a
10 mW He–Ne laser operating at a wavelength of 633 nm.
Measurements were performed in a low ionic strength buffer,
1.0 mM HEPES buffer adjusted to pH 7.4. The mean value and
standard deviation for each sample was calculated from at
least five measurements.
Transmission electron microscopy. Morphology of the par-
ticles was examined using a transmission electron microscope
(TEM) (Jeol Jem 1010 electron microscope, Japan). A sample of
particle suspension was diluted with a solution of phospho-
tungstic acid (3% w/v, pH 7.4) and observed under TEM. One
drop of sample was placed for 1 minute on a copper grid
coated with a formvar carbon film. The excess of sample was
wicked away with the aid of filter paper prior to imaging by
TEM.
Thermal transition temperatures. Thermal transition temp-
eratures (TTTs) of NPs were determined via turbidity. The
change of turbidity of nanoparticle suspensions (in cell culture
media) in response to change of temperature was investigated
Paper Biomaterials Science
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using UV/VIS spectrophotometer (Beckman, DU 800). Absor-
bance measurements were taken at 550 nm. Cycles were pro-
grammed to run from 20–90 °C (ramp rate of 1 °C min−1).
Determination of R6G encapsulation efficiency and loading in
nanoparticles
The amount of R6G encapsulated was determined by a direct
method. Freeze-dried R6G-labelled NPs were dissolved in
DMSO, and the absorbance at 540 nm were determined using
a UV/VIS spectrophotometer (Beckman, DU 800). With the aid
of a standard curve of known concentrations of R6G in the
same organic solvent, the amount of R6G was determined.
The influence of different theoretical drug loadings on the
drug incorporation efficiency was investigated. Encapsulation
and recovery were calculated using the equations below.19
Theoretical drug loading ðwt%Þ ¼ ðMass of drug used in
formulation=Mass of
copolymer used in
formulationÞ  100
Practical drug loading ðwt%Þ ¼ ðMass of drug in NPs=Mass of
NPs recoveredÞ  100
Encapsulation efficiency ð%Þ ¼ ðMass of drug in NPs=Mass of
drug used in formulationÞ
 100
NP recovery ðyieldÞ ð%Þ ¼ ðMass of NPs recovered=Theoretical
mass of copolymer;drug and
any other stabilisers used
in formulationÞ  100
In vitro release of R6G
The R6G-labelled NP suspension (1 mL, about 4 mg mL−1) and
1 mL of PBS (pH 7.4) were added to a dialysis bag (molecular
weight cut-off 6–8 kDa), and then placed in a beaker with
phosphate buffered saline (PBS) (pH 7.4, 15 mL). Dialysate
(15 mL) was removed from the beaker and an equal volume of
fresh PBS was added at regular time intervals. The fluorescent
solution was measured at λex = 525 nm, λem = 550 nm, slit
widths (ex./em.) = 2.5/2.5 nm (Hitachi F-4500 fluorescence
spectrophotometer, Hitachi Scientific Instruments, Finchamp-
stead, UK). The amount of fluorescent dye was calculated by
comparison with a standard curve of R6G fluorescence in PBS
(pH 7.4). Effect of temperature was investigated by studying
the release at 37 and 42 °C.
Cell culture
Human breast adenocarcinoma MCF7 cells were maintained
on RPMI-1640 media supplemented with L-glutamine, sodium
bicarbonate and 10% fetal bovine serum (FBS) at 37 °C and
5% CO2.
Cellular uptake of NPs by MCF7 cells
To investigate the effect of temperature on cell uptake, three
R6G-loaded NPs with different thermal transition tempera-
tures (TTTs) were incubated with MCF7 cells at 37 and 40 °C.
Fluorescence microscopy
Cells were seeded in four 12-well plates that contained steri-
lised cover-slips at a concentration of 100 000 cells per well. A
day after seeding, the media was replaced with media contain-
ing 200 μg mL−1 of R6G-loaded nanoparticles (NP1, NP2, NP3).
The cells were incubated at 37 °C or 40 °C for 2 h. Sub-
sequently, media was removed and cells were washed three
times with PBS, fixed for 10 min in 1% paraformaldehyde and
again washed three times. For nuclei staining, DAPI standard
solution (Invitrogen, 1 drop) was added to each well and the
stain allowed to enter the cells over a period of 10 min fol-
lowed with washing. Cover-slips were then mounted onto
microscopy slides to protect the samples. Microscopy images
were obtained with a Leica DM IRB instrument. Images were
recorded using a Leica DC200 camera and processed using DC
viewer, version 3.2.0.0 software (Leica Microsystems,
Germany). All microscopy gain and offset settings were main-
tained constant throughout the study.
Fluorescence activated cell sorting (FACS) flow cytometry
Cells were seeded at a concentration of 500 000 cells per well
in 6-well plates for 24 h. Growth media was replaced with for-
mulations containing 200 μg mL−1 of R6G-loaded nanoparti-
cles (NP1, NP2, or NP3). The cells were incubated at 37 or
40 °C for 2 h. Cells were then washed three times with PBS
and a cell suspension was created using trypsin/EDTA. Cell
suspensions were diluted in growth media to stop the trypsini-
sation process, centrifuged and washed three times with PBS.
Cells were finally re-suspended in 500 μL of PBS and immedi-
ately analyzed with a flow cytometer (Beckman Coulter FC500;
High Wycombe, Buckinghamshire, UK) with XL SYSTEM II™
software using a 488 nm laser for excitation of R6G and a band
centred at 585 nm for detection of fluorescence. Flow cyto-
meter channel voltage and gain were maintained constant
throughout the analysis. Approximately 10 000 cell detection
events were evaluated for forward and side scatter character-
istics to determine the trend of R6G-labelled NP taken up by
cells.
Determination of paclitaxel content in nanoparticles
The amount of drug encapsulated was determined by a direct
method. Freeze dried nanoparticles were weighed and dis-
solved in acetonitrile and vigorously vortexed to get a clear solu-
tion. Samples were analysed by HPLC at room temperature
using a Hewlett-Packard HP1050 (Hewlett-Packard, Milano,
Italy) on a Lichrosphere 100 RP-18 (5 μm) end-capped column
equipped with a Hypersil 100 RP-18 (5 μm) guard cartridge
(4 mm × 4 mm i.d.) and eluted isocratically with acetonitrile/
water (70/30 v/v). The flow rate was fixed at 1 mL min−1 and
operating pressure 1280 psi. The effluent was monitored at
Biomaterials Science Paper
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227 nm. PTX solutions of known concentrations in the range
2.5–100 μg mL−1 were used to produce a standard curve from
which concentrations of unknowns were determined.
In vitro drug release study
PTX-loaded NPs prepared by the modified IPD method (with
1% theoretical drug loading) were used for in vitro release
study. The PTX-loaded NP suspension (1 mL, about 4 mg
mL−1) and 1 mL of the media were added to a dialysis bag
(molecular weight cut-off 6–8 kDa), and then placed in a
beaker with PBS (pH 7.4 or 4.5, 10 mL). Dialysate (10 mL) was
removed from the beaker and an equal volume of fresh media
was added at regular time intervals. The collected dialysates
were analysed with HPLC as described previously. The effect of
temperature was investigated by studying the release at 37 and
42 °C.
In vitro anti-tumour activity (MTT assay)
Human breast adenocarcinoma MCF7 cells were seeded in
96-well plates at the density of 10 000 viable cells per well and
incubated for 24 h in growth media to allow cell attachment.
The cells were then incubated with aqueous dispersions of free
PTX (control), PTX-loaded nanoparticles (NP4) (experimental)
or drug-free nanoparticles (4 mg mL−1) for 24 h at 37 or 40 °C
in PBS (pH 7.4). At pre-determined times, the formulations
were replaced with media containing 3-[4,5-dimethylthiazol-2-
yl]-3,5-diphenyl tetrazolium bromide (MTT) and cells were
then incubated for additional 4 h. The MTT-containing solu-
tion was aspirated off and DMSO was added to dissolve the
formazan crystals. Absorbance was measured at 570 nm using
an absorbance microplate reader (Dynex Technologies, USA).
Untreated cells were taken as control with 100% viability. Cell
viability was expressed using the following equation:
Cell viability ð%Þ ¼ ðAbsexp:=AbscontrolÞ  100
where Absexp. and Abscontrol represent the amount of formazan
determined for cells treated with the different formulations
and for control cells (non-treated), respectively. The exper-
iment was performed in triplicates and the results are
expressed as mean values ± standard deviation.
Statistical analyses
All statistical analyses were performed using GraphPad Prism
5.04 (GraphPad Software Inc.).
Results and discussion
Synthesis of PLGA-b-(PEGMEMA-co-PPGMA)
Poly[lactide-co-glycolide]-block-poly[poly(ethylene glycol)mono-
methyl ether methacrylate-co-poly(propylene glycol) methacry-
late] (PLGA-b-(PEGMEMA-co-PPGMA)) was synthesised as
previously described.17 Briefly, a PLGA block was synthesised
by ring-opening polymerisation of lactide and glycolide in
melt using tin(II) 2-ethyl hexanoate as catalysis and tetraethy-
lene glycol mono 2-bromoisobutyrate as an initiator. The
resulting bromide terminated PLGA was then used as the
initiator in AGET ATRP of PEGMEMA/PPGMA.20 The
PEGMEMA/PPGMA feed ratio (Table S1, ESI†) was varied to
produce polymers with varying thermal transition tempera-
tures (TTT). Molecular weights (Mn) and polydispersity indices
(Mw/Mn) for the polymers used are given in Table 1.
Formulation and physicochemical characterisation of PLGA-b-
(PEGMEMA-co-PPGMA) particles encapsulating rhodamine 6G
Particles encapsulating the fluorophore rhodamine 6G (R6G)
were formulated using the interfacial polymer deposition (IPD,
or “nanoprecipitation”) method described by Fessi et al.18 R6G
loading was targeted at 0.1, 0.25 and 0.4 wt%. As expected
increasing theoretical loading resulted in an increase in practi-
cal loading (encapsulation) from 0.05 to 0.13 wt%, albeit with
a reduction in encapsulation efficiency from 48% to 32% pre-
sumably due to a limiting encapsulation capacity of the par-
ticles for R6G (Table S2, ESI†). Consequently, subsequent
formulations of R6G-loaded particles were produced using a
theoretical loading of 0.25 wt%. Particles with varying thermal
transition temperatures were formulated by using polymers
with different PEGMEMA/PPGMA ratios. Particle size distri-
butions, surface charge and dye loading were found to be com-
parable between formulations (NP1–3; Table 1, entries 1–3).
In vitro release of rhodamine 6G from PLGA-b-(PEGMEMA-co-
PPGMA) particles
In order to test any intrinsic changes in drug release due to
nanoparticle thermal responses over an approximate physio-
logical/hyperthermia range, the release of rhodamine 6G from
NP2 was studied at 37 and 42 °C, i.e. above and below these
nanoparticles’ TTT, in PBS at pH 7.4. Within the first 8 hours,
approximately 30% of encapsulated dye was released both
above and below the thermal transition temperature. After
Table 1 Characterisation of R6G-and PTX-loaded nanoparticles studied in vitro
Particle
Polymer
used
Mn
a
(kDa) Mw/Mn
a
Rh ± SD
b
(nm)
ζ potential ± SD
(mV)
Theoretical
drug loading
(wt%)
Practical drug
loading (wt%)
Encapsulation
efficiency (%)
NP recovery
(yield) (%)
Transition
temperaturec
(°C)
NP1 P1 20.4 1.3 26.1 ± 9.1 −0.6 ± 2.2 0.25 0.113 ± 0.007 45.0 ± 2.9 96.1 ± 1.7 33
NP2 P2 19.8 1.3 25.4 ± 12.0 −1.2 ± 2.2 0.25 0.112 ± 0.006 44.8 ± 2.3 96.0 ± 1.1 39
NP3 P3 17.2 1.3 26.3 ± 12.8 −1.9 ± 3.2 0.25 0.117 ± 0.005 46.8 ± 1.8 96.8 ± 3.8 56
NP4 P2 19.8 1.3 31.5 ± 11.7 N.D. 1.0 0.76 ± 0.01 76.2 ± 1.2 80.4 ± 0.03 39
aDetermined by gel permeation chromatography against polystyrene standards. bDetermined by dynamic light-scattering after dye/drug
incorporation. cDetermined by cloud point measurements.
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24 h the cumulative dye release only increased slightly to
approximately 34% (Fig. 2A). This rapid early release was likely
to derive from release of dye entrapped within the polymer
corona, or loosely physisorbed to the surface of the PLGA core,
rather than truly encapsulated within the core. This assertion
was supported by the slightly faster release in the first 3 h at
42 °C compared to 37 °C, where dye entrapped in the corona
would be rapidly excluded upon chain collapse.
Effect of temperature on cellular uptake of thermoresponsive
nanoparticles with different thermal transition temperatures
The effect of temperature on cellular uptake of nanoparticles
NP1–3 was determined in the MCF-7 breast carcinoma cell
line. All particle batches had similar sizes, zeta potentials and
dye loading, such that the most important differences in their
properties were likely to be their various thermal transition
temperatures (33, 39 and 56 °C respectively). These transition
temperatures were chosen to provide the three possible
hydration states under physiological conditions, i.e. (i) perma-
nently collapsed, (ii) hydrated under normal conditions but
collapsed under mildly hyperthermic conditions, and (iii) per-
manently hydrated. Cells were incubated with the particles at
37 and 40 °C for 2 h before washing and analysis by flow cyto-
metry and fluorescence microscopy.
Mean fluorescence intensity (MFI), measured by flow cyto-
metry of cells treated with NP1–3 is given in Fig. 2B. It is
evident that temperature had no effect on MFI after treatment
with NP1 or NP3. However, the MFI of cells treated with NP1
was significantly higher than for those treated with NP3 at
both temperatures (P < 0.001, 2-sided unpaired Student’s
t-test). In contrast, MFI of cells treated with NP2 was signifi-
cantly affected by temperature (P < 0.001, 2-sided paired
Student’s t-test) with greatly enhanced fluorescence for cells
incubated above the TTT of the particles. The temperature-
dependent nature of cellular fluorescence was confirmed by
microscopy (Fig. 2C). Again it is evident that fluorescence of
cells treated with NP1 or NP3 was independent of incubation
temperature while fluorescence of cells treated with NP2 was
highly dependent on the changes temperature, specifically 37
and 40 °C, which are in fact below and above the TTT for NP2.
As the release profile of R6G from NP2 was only slightly
affected by temperature the greatly enhanced fluorescence in
cells treated above the thermal transition temperature was
unlikely to be due to increased uptake of free R6G but instead
due to increased particle uptake by the cells. This hypothesis
was supported by the observation that cells treated with NP1
and NP3 showed fluorescence intensities correlating to treat-
ment with particles above their TTT; i.e. cells treated with NP1
at 37 °C and 40 °C exhibited high rhodamine fluorescence as
both temperatures were above the TTT for NP1, whereas low
fluorescence was observed for cells treated with NP3 at both
temperatures (TTT for NP3 is 56 °C). The enhanced uptake of
particles above their thermal transition temperature was thus
in agreement with the report of Salmaso et al. for non-ligand
targeted pNIPAM-coated gold nanoparticles with MCF-7 cancer
cell lines.12 We then proceeded to evaluate the potential of our
nanoparticle assembly for the targeted delivery of a clinically
pertinent cytotoxic agent, paclitaxel.
Formulation of nanoparticles encapsulating paclitaxel
Paclitaxel (PTX) containing particles were formulated in a
similar manner to the R6G particles (vide supra). Polymer
Fig. 2 (A) Cumulative release of rhodamine 6G from NP2 nanoparticles (for-
mulated from polymer 2) at below (37 °C) and above TTT (42 °C). Points are
mean ± one standard deviation for 2 replicates. (B) Mean of the fluorescence
intensity of MCF7 cells exposed to R6G-loaded nanoparticles for 2 h as a func-
tion of temperature (below and above TTT) obtained by flow cytometry. Circles
represent individual measurements, lines represent mean values and error bars
represent one standard deviation. ***P < 0.001 for NP2 at the two temperatures.
(C) Fluorescence micrographs of MCF-7 cells treated with thermoresponsive
nanoparticles over clinically relevant temperature range (37 vs. 40 °C). (D)
Higher resolution confocal micrographs of MCF-7 cells treated with R6G-loaded
NP2 at 37 °C and 40 °C, showing enhanced signal from NP2-encapsulated R6G
in cells. Nuclei are stained with DAPI (blue) while particles carry rhodamine 6G
(red).
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solutions (50 or 100 mg in acetone) containing PTX (0.25, 0.5
or 1 mg mL−1) were precipitated into buffer as before
(Table S3, ESI†). A PTX concentration of 0.5 mg mL−1 resulted
in relatively high drug loading (0.4 and 0.58 wt%) with good
particle recovery. In contrast, increasing PTX concentration to
1 mg mL−1 resulted in poor particle recovery (42 and 64%).
In order to increase encapsulation efficiency, formulation
with a modified IPD method was attempted. Here, polymer
and PTX were dissolved in acetone and the solvent was allowed
to evaporate. The residual material was redissolved in acetone
and precipitated into buffer as before. This method increased
encapsulation efficiency from 50 to 76% while increasing par-
ticle recovery from 64 to 80% (Table S3, ESI†) and was sub-
sequently used for formulation of particles, i.e. NP4, tested
here.
Release of paclitaxel from PLGA-b-(PEGMEMA-co-PPGMA)
nanoparticles
The release of encapsulated PTX was studied at pH 7.4 and 4.5
as these are representative of extracellular and lysosomal pH,
respectively. In both cases, release above and below the TTT
was quantified (Fig. 3A). At pH 7.4, less than 10% of encapsu-
lated PTX was released after 24 h and temperature had no
effect on release rate. At pH 4.5, PTX release was more rapid
with approximately 25% release after 24 h; again little effect of
temperature was observed. The increased release rate at lower
pH is expected as under these conditions the degradation of
the PLGA core is considerably faster than at neutral pH allow-
ing more PTX to diffuse into solution. The differences in
release rates also imply that these particles would be suited to
selective delivery as significant drug release would only occur
at low, i.e. lysosomal, pH rather than the near neutral pH of
the circulatory system thus reducing off-target effects.
In vitro cytotoxicity of paclitaxel-loaded nanoparticles
The cytotoxicity of PTX-loaded nanoparticles was assessed in
an in vitro model with the human breast adenocarcinoma cell
line MCF-7. Cells were incubated with either free PTX or NP4
at normal physiological (37 °C) or mildly hyperthermic (40 °C)
temperature. Cellular metabolic activity was determined using
an MTT assay (Fig. 3B). Free PTX displayed the same effect on
metabolic activity at both temperatures indicating that temp-
erature variation over the 37–40 °C range did not affect uptake
of the free drug or its inherent efficacy. At 37 °C, NP4 displayed
toxicity comparable to, or lower than, that of free PTX implying
that encapsulation reduced drug availability presumably due
to reduced particle uptake when the corona was hydrated. Con-
versely, at 40 °C toxicity of NP4 was greater than that of free
PTX most likely due to increased particle uptake and release of
PTX within the cell.
When considered together, the data is strongly suggestive
of a thermoresponsive polymer-mediated mechanism for cell
entry, and an enhanced cytotoxicity through increased uptake
above the thermal transition temperature of the nanoparticles.
Similar thermoresponsive cytotoxicity was reported for
thermo-sensitive micelles21 formed by coupling dicarboxylated
poly(ethylene glycol) (PEG; Mw 2000) with poly(L-lactic acid)/
poly(ethylene glycol)/poly(L-lactic acid) (PLLA/PEG/PLLA) tri-
block copolymers. The PLLA–PEG–PLLA micelles, in this case
with encapsulated doxorubicin (DOX), showed 20-fold
enhanced cytotoxicity at 42 °C against Lewis lung carcinoma
cells when compared to that at 37 °C although the total
amount of released DOX at 42 °C was only two times higher
than that at 37 °C. This result was attributed to thermal
switching of the PLLA–PEG–PLLA micelle to a more hydro-
phobic surface at the higher temperature, facilitating internal-
ization of DOX-loaded micelles into the cells. Accordingly,
there was clear precedent for a polymer-response-mediated
uptake effect, though in our case we used responsive core–
Fig. 3 (A) Release of paclitaxel from nanoparticles NP4 at pH 4.5 and 7.4, and
above and below the thermal transition temperature. (B) Relative metabolic
activity as measured by an MTT assay of MCF-7 cells after treatment with free
paclitaxel or NP4 for 24 h above and below the thermal transition temperature.
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shell nanoparticles rather than thermoresponsive liposomes22
and thermo-responsive micelles21 used previously.
It is important to note that cytotoxicity effects observed in
the variable temperature studies were not due to intrinsic
temperature effects on the cells. Prior studies have shown that
MCF-7 cells can tolerate temperatures up to 43 °C, i.e. above
those used in our assays, without marked changes in viability
or activity.23–25 The MTT assays in our study (Fig. S3, ESI†)
showed that MCF7 cells showed similar viability at both incu-
bation temperatures (i.e. 37 and 40 °C), a result consistent
with prior literature showing that moderate hyperthermia (i.e.
38–42 °C) has no acute cytotoxic effect on cells.26,27 In
addition, no cytotoxic activity was observed for the drug-free
nanoparticles as cell viability was found to be in the range of
90–100% for applied polymer concentrations up to 4 mg mL−1
across both investigated temperatures (Fig. S3, ESI†). The bio-
compatibility of these NPs was in good accord with studies of
related polymers.28–31 The results also demonstrated, as with
previously published reports,21 that at 37 °C comparable cyto-
toxicity was observed for both free PTX and PTX-loaded NPs.
These findings suggest that reduced side effects would be
expected for these thermoresponsive NPs under normal phys-
iological conditions. However, the incorporation of PTX into
nanoparticles may enhance its anti-tumoural activity com-
pared to the free PTX, which is attributed to the higher cellular
uptake of NPs compared to the free drug.32 For example,
Westedt et al. evaluated the anti-tumoural activity of free PTX
and PTX-loaded PVA-g-PLGA NPs using primary RbVSMC cells
in culture.33 Their results demonstrated that at high drug
loading levels, free PTX was less toxic than when incorporated
into nanoparticles. Similarly, the Preat group evaluated the
in vitro cytotoxic activity of Taxol® and PTX-loaded PEG–PLGA
NPs by the MTT assay using HeLa cell lines.34 In this example
the IC50 value for HeLa cells decreased from 15.5 μg mL−1 for
Taxol® to 5.5 μg mL−1 for the PTX-loaded NPs. Thus, in
certain cases and for specific cell lines, one could anticipate
an extra advantage for incorporation of PTX into responsive
nanoparticles, as further enhanced uptake into tumour cells
could occur relative to normal cells.
Although not investigated directly in this study, the results
are encouraging for future in vivo applications since for deli-
very to tumours, PTX-loaded nanoparticles are likely to be
administered intravascularly to circulate in a pH 7.4 environ-
ment. At this pH, minimal release of PTX is desired to mini-
mise off-target effects. However, in the acidic (pH 5–6)
environment typical of lysosomes (to which the NPs would
probably be routed during the cellular uptake) the data
showed enhanced release of PTX from the NP4 materials. This
effect would have contributed to the enhanced cytotoxicity of
nanoparticle delivered PTX compared to free drugs as apparent
in the MTT assay, since the endolysosomal pathway is the
‘default’ route for nanoparticles of this type.35 Thus, in
addition to the temperature-mediated localisation due to the
thermoresponsive shell, the PTX-loaded pPLGA-b-(PEGMEMA-
co-PPGMA) NPs have the properties of enhanced release in
response to the physiological changes in the local
environment. Similar pH dependent release profiles have been
observed previously with PLGA nanoparticles encapsulating
doxorubicin36 and rhodamine 6G37 due to accelerated degra-
dation of the polymer at acidic pH. The fact that these profiles
have been obtained with both hydrophilic compounds (DOX,
R6G) and hydrophobic drugs (PTX) points to the key advantage
of nanoprecipitated drug delivery systems, i.e. their ability to
incorporate both hydrophilic and hydrophobic drugs.38,39
For practical application and regulatory requirements, drug
delivery systems need to be well-defined. The thermorespon-
sive systems in this work were prepared via controlled poly-
merisation techniques (ATRP and ROP), enabling good control
over molar masses and polydispersities, as well as well-defined
thermal phase transitions.40 Clearly, these thermal transitions
are highly sensitive to the molar ratios of the co-monomers
which can be defined through monomer feed and order of
addition. Variations in molecular weight could, in principle,
be used to manipulate the encapsulation efficiency of drug
compounds as well as their release profiles. Depending on the
desired target and clinical applications of these systems, “On–
Off” release or thermoresponsive release profiles could thus be
tailored by varying the ratios of the monomers or by incorpor-
ation of different functionalities. Recent studies by the Chilk-
oti group have shown that precisely engineered biopolymers
based on elastin-like-polypeptides (ELPs) can be tuned to self-
assemble into nanoparticles in vivo over narrow temperature
ranges, and that conjugates of these polypeptides with doxoru-
bicin can target tumours effectively.13,41 These impressive data
show that extension of the thermally-targeted nanoparticle
delivery mechanism can operate in an animal model. We envi-
sage that our modular core–shell synthetic polymer nanoparti-
cles delivery can be used in an analogous means to ELP-
derived responsive nanoparticles, but across a wider range of
therapeutic compounds and broader formulation conditions.
Experiments to evaluate these hypotheses are in progress.
Conclusions
In conclusion, we have demonstrated that particles formulated
from PLGA-block-(PEGMEMA-co-PPGMA) polymers are suitable
for encapsulation and temperature controlled delivery of
drugs. The reduced cytotoxicity of encapsulated paclitaxel
below the thermal transition temperature indicates the suit-
ability of these particles for systemic delivery where minimal
drug release to non-target sites is essential. As cellular uptake
may be triggered by only a small increase in temperature,
these particles hold promise for delivery to hyperthermic
tissues such as those found at sites of inflammation or in
tumours. Additionally, induced hyperthermia using thermal
ablation techniques such as high-intensity focused ultrasound,
should enable these materials to be activated for uptake by an
external trigger, thus enabling targeting even where natural
hyperthermia is absent. Current studies are investigating the
potential for these systems to be used in vivo for targeted deli-
very of anticancer agents.
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